A clinical trial on the efficacy of combination therapy with immune-cell therapy(dendritic cell vaccine) and immune check point inhibitor for malignant tumor - Combination therapy with immune-cell therapy and immune check point inhibitor

Takimoto Rishu0 个研究点目标入组 40 人开始时间: 2019年9月19日最近更新: 2024年4月1日

适应症

试验速览

The study is terminated due to lack of hope for case enrollment.

•A patient MUST:
•1) Be diagnosed with relapsed or advanced malignant tumor.
•2) Have a measurable lesion of tumor.
•3) Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1.
•4) Be administered immune check point inhibitor and immune-cell therapy within 4 weeks at the clinic.
•5) Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed.
•6) Provide agreement of the attending doctor to participate in this study.
•7) Have a backup hospital in the case of emergency.
•8) Provide written consent to participate in this study.

•A patient MUST NOT:
•1) Have a positive result of HIV antibody.
•2) Have a T cell-, NK cell-derived malingnant lymphoma/leukemia (in the case of activated immune-cell therapy).
•3) Be post allogenic bone marrow transplantation.
•4) Have a history of a serious adverse event due to immune check point inhibitor.
•5) Be a female who is pregnant, lactating, or with a possibility of pregnancy.
•6) A patient who is judged as inadequate for enrolment by doctors is excluded

发起方

Takimoto Rishu